Should mefenamic acid be taken every 6 hours or every 8 hours?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mefenamic Acid Dosing Interval

Mefenamic acid should be taken every 6 hours, not every 8 hours, according to FDA-approved labeling.

Standard Dosing Regimen

The FDA-approved dosing for mefenamic acid is 1:

  • Initial dose: 500 mg
  • Maintenance dose: 250 mg every 6 hours as needed

This applies to both:

  • Acute pain management in adults and adolescents ≥14 years
  • Primary dysmenorrhea (starting with onset of bleeding)

Clinical Context and Duration

For acute pain: Treatment typically should not exceed one week 1.

For dysmenorrhea: Effective treatment initiated at the start of menses should not be necessary for more than 2-3 days 1. Clinical trials demonstrated that a 500 mg initial dose followed by 250 mg every 6 hours was significantly superior to placebo across all parameters including pain assessment, need for concurrent analgesia, and symptom severity 1.

Pharmacokinetic Rationale

The every-6-hour dosing interval is supported by mefenamic acid's pharmacokinetic profile 1:

  • Half-life: 2-4 hours
  • Time to peak concentration: 2-4 hours
  • No drug accumulation with multiple dosing

The short elimination half-life necessitates more frequent dosing to maintain therapeutic drug levels throughout the day.

Common Pitfall to Avoid

Do not confuse mefenamic acid dosing with other NSAIDs that may be dosed every 8 hours (such as ibuprofen, diclofenac, or ketoprofen as noted in pediatric guidelines 2). The every-8-hour interval mentioned in one older research study 3 contradicts the FDA-approved labeling and should not be followed—always defer to the official FDA dosing recommendations 1.

Important Safety Considerations

  • Use the lowest effective dose for the shortest duration consistent with treatment goals 1
  • Not adequately studied in pediatric patients <14 years of age 1
  • Contraindicated in patients with pre-existing or significantly impaired renal function 1
  • Dose adjustments may be necessary in hepatic or renal dysfunction 1

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.